AGN:CSE; AGNPF:OTCQB; AGW:FSE

Algernon Pharmaceuticals Inc.

Algernon is a clinical stage drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
Algernon has filed new intellectual property rights globally for its lead drug NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation.

AGN:CSE AGNPF:OTCQB AGW:FSE

View Company News

Visit Company Website

Expert Comments:

Biotech Given Go-Ahead to Proceed with Phase 3 COVID-19 Study
(1/20/21)

Algernon Pharmaceuticals reported that it has been granted approval from the Data and Safety Monitoring Board to conduct a Phase 3 Study of Ifenprodil for SARS-CoV-2.

Pharma Developer Outlines 2021 Clinical Program Initiatives
(1/8/21)

Algernon Pharmaceuticals provided an update detailing its plans for 2021 clinical trials.

Biopharma Recaps 2020 Accomplishments in COVID-19, Idiopathic Pulmonary Disease
(1/4/21)

Algernon Pharmaceuticals reports that it is aggressively advancing its repurposed drug, Ifenprodil.

Clive Maund, CliveMaund.com

(12/28/20)

"The good news with Algernon Pharmaceuticals Inc. is that the stock has now arrived at a much stronger long-term support level in a deeply oversold state, so the least we can expect is a significant bounce from here. On Thursday there was a moderately bullish candle on strong volume with it closing well off the lows, which suggests that it may be reversing here or at least have hit bottom."

Pharma Developer Provides Interim Update from Phase 2b Ifenprodil COVID-19 Study
(12/21/20)

Algernon Pharmaceuticals provided additional interim data from its Phase 2b/3 Ifenprodil COVID-19 study outlining several potential primary endpoints for the Phase 3 portion of the trial.

Analyst: Small Cap's Interim COVID-19 Trial Data Show 'Two Positive Early Trends'
(12/16/20)

Partial Phase 2b results of this evaluation of Algernon Pharmaceuticals' antagonist are provided in a Mackie Research Capital Corp. report.

Pharma Developer Reports Interim Data Is Trending Positively in Phase 2b/3 COVID-19 Trial
(12/16/20)

Algernon Pharmaceuticals reported that interim data from its Phase 2b/3 Ifenprodil COVID-19 study is showing very positive signs of reducing the need for mechanical ventilators.

André Uddin, Mackie Research Capital

(12/15/20)

"Algernon Pharmaceuticals Inc. reports interim results of a COVID-19 Phase 2b/3 trial with Ifenprodil. . .The results showed two positive early trends in high-dose ifenprodil at Day 15: (i) fewer patients required mechanical ventilation and (ii) the reduction of the NEWS score (used to monitor patient status) was quicker, which could potentially translate to a faster recovery down the road. . .We are maintaining our SPECULATIVE BUY rating and TP of $0.80/share. AGN remains a high risk high reward investment opportunity."

Clive Maund, CliveMaund.com

(12/8/20)

"Algernon Pharmaceuticals Inc. is now in a vigorous uptrend. It has paused for a rest in recent days with a small bull Pennant believed to be forming. Current light volume and strong Accumulation line suggest that another upleg is imminent."

Pharma Developer Raises Enrollment Goal for Multinational Phase 2b/3 COVID-19 Trial
(11/25/20)

Algernon Pharmaceuticals reported it has enrolled 154 patients in its Phase 2b/3 human study of Ifenprodil for COVID-19 and is increasing the pool to 168 patients to allow for attrition.

Biotech Plans to Release Interim Data for Phase 2b/3 COVID-19 Trial in December
(11/11/20)

Algernon Pharmaceuticals reported it intends to announce the interim results from its Ifenprodil Phase 2b/3 COVID-19 human study during the first week of December 2020.

Multinational Phase 2b/3 COVID-19 Study Approved to Continue
(11/2/20)

Two doses of Algernon Pharmaceuticals' NP-120, or Ifenprodil, are being tested for safety and efficacy.

Biopharma Announces Pulmonary Fibrosis Trial Now 25% Enrolled
(10/14/20)

Five sites in Australia and New Zealand are participating in this study of Algernon Pharmaceuticals' drug.

StreetSmart Live! Presents Algernon Pharmaceuticals
(10/8/20)

Algernon Pharmaceuticals CEO Christopher Moreau and guests fund manager Steve Palmer, Dr. Mark Swaim and Tony Pullen discuss the company's upcoming catalysts and events.

Biopharma's Multinational COVID-19 Study Hits 75% Enrollment Mark
(10/5/20)

Algernon Pharmaceuticals expects completion of the clinical trial next month and data readout by year-end.

Pharmaceutical Firm Completes Enrollment of 100 Patients in Phase 2b/3 COVID-19 Clinical Trial
(9/30/20)

Algernon Pharmaceuticals reported it has now enrolled 100 of 150 planned patients in its Phase 2b/3 human study of Ifenprodil for treatment of COVID-19.

Pharmaceutical Firm Reaches 50% Enrollment Mark in Phase 2b/3 Ifenprodil COVID-19 Study
(9/23/20)

Algernon Pharmaceuticals reported it has enrolled the first 75 of 150 patients in a multinational Phase 2b/3 human study of Ifenprodil in treating SARS-CoV-2.

Pharma Greenlighted to Continue Multinational COVID-19 Study
(9/18/20)

This confirms the safety of NP-120, the drug Algernon Pharmaceuticals is evaluating in this human trial.

All Penny Stocks

(8/24/20)

"What a spectacular run junior biotech Algernon Pharmaceuticals Inc. has made since late-November. The stock run-up is largely predicated on one virus, COVID-19. With a brief pullback over the last few months, we think it is time to revisit this stock as the technical stars may be aligning for one more major push higher."

André Uddin, Mackie Research Capital

(8/19/20)

"We are initiating coverage of Algernon Pharmaceuticals Inc. with a Speculative Buy recommendation and a target price of $0.80/share. . .Algernon is focused on developing repurposed small molecules for new disease indications – these drug candidates have been already approved in ROW markets (but not approved in the U.S. or Europe). . .Algernon's lead product, ifenprodil (a marketed drug in Japan for circulatory disorders) is being repurposed for COVID-19, idiopathic pulmonary fibrosis (IPF) and chronic cough."

Pharmaceutical Firm Enrolls First US Patient in Phase 2b/3 Ifenprodil COVID-19 Trial
(8/17/20)

Algernon Pharmaceuticals reported it has enrolled the first U.S. patient in its multinational Phase 2b/3 human study of Ifenprodil for use in treatment of SARS-CoV-2.

Baystreet

(8/12/20)

"Algernon Pharmaceuticals Inc. is betting that this quiet and unassuming safe generic drug, Ifenprodil, may soon become a global blockbuster. . .the company recently announced the first patient has been enrolled in its multinational human Phase 2b/3 COVID trial of Ifenprodil. . .Phase 2b data are expected before 2020E."

Pharmaceutical Firm Doses First Patient in Phase 2 IPF and Chronic Cough Trial

(8/8/20)

Algernon Pharmaceuticals reported that the first patient has been dosed in the Phase 2 human study of Ifenprodil for treatment of idiopathic pulmonary fibrosis and chronic cough.

Experts Following This Company

Knox Henderson
Clive Maund – CliveMaund.com
	André Uddin – Mackie Research Capital

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.See disclaimer for more details.

Investing Highlights

	Algernon Pharmaceuticals Inc. (OTC: AGNPF) (CSE: AGN) is one of the few companies still flying under the radar of the masses, potentially giving one of the last “ground floor” looks at a coronavirus stock before a pending breakout
	Algernon Pharmaceuticals Inc. (OTC: AGNPF) (CSE: AGN) already has a proven drug that has a strong safety history and was developed by one of the top names in biotech, Sanofi.
	Algernon Pharmaceuticals Inc. (OTC: AGNPF) (CSE: AGN) has already received positive Feedback from U.S. FDA for Ifenprodil COVID-19 Human Trial and is now approved for a Phase 2 clinical study in South Koreau cleared for a Phase 2b/3 human trial in CA

catalyst Calendar

Q2 2020	US FDA IND submission Phase 2b/3 May 15th, 2020
Q2 2020	First patient in Phase 2 study in South Korea – May 15th , 2020
Q2 2020	Ethics and regulatory approval for Phase 2 idiopathic pulmonary fibrosis (IPF) & chronic cough study

Algernon Pharmaceuticals Inc. Content

Corporate Presentation 2nd Quarter

Fact Sheet April 2020